பெட்ரிகோர் சுகாதாரம் மூலதனம் மேலாண்மை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Leukocare Raises USD 17 5M in Financing

Leukocare Raises USD 17 5M in Financing
finsmes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finsmes.com Daily Mail and Mail on Sunday newspapers.

United statesMichael schollTadd wesselUnited states basedPetrichor healthcare capital managementManaging partnerManaging directorOrbimed advisorsChief executive officerஒன்றுபட்டது மாநிலங்களில்மைக்கேல் பள்ளிதாதித் வெசெல்ஒன்றுபட்டது மாநிலங்களில் அடிப்படையிலானதுபெட்ரிகோர் சுகாதாரம் மூலதனம் மேலாண்மைநிர்வகித்தல் கூட்டாளர்நிர்வகித்தல் இயக்குனர்

ITM Raises EUR 90 M (USD 109 M) to Accelerate Precision Oncology Pipeline and Support Ongoing Phase 3 Clinical Program

(0) Financing led by Petrichor Healthcare Capital Management strengthens company s global position as a leader in precision oncology and the field of Targeted Radionuclide Therapy ITM AG announced today the successful close of a convertible loan financing totaling EUR 90 million (USD 109 million) led by Petrichor Healthcare Capital Management with participation of additional undisclosed investors. The proceeds will support the expansion of ITM s precision oncology pipeline as well as fund late-stage development and market access activities for lead candidate, n.c.a. 177Lu-Edotreotide, currently in a phase III trial in gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Under the terms of the agreement, the loan will convert into shares of ITM in the event of certain future financial or other corporate development transactions. Further details of the financing were not disclosed.

David katonaNicola scharrerKostenloser wertpapierhandelSteffen schusterUdoj vetterTadd wesselIsotopen technologienDistrict courtHead of marketing communicationsTrophic communicationsDeutsche bank freiburgFortress investment groupHead of business developmentPetrichor healthcare capital managementTargeted radionuclide therapyChief executive officer

ITM Closes Convertible Loan Financing Totaling EUR90M

ITM Closes Convertible Loan Financing Totaling EUR90M ITM, a Munich, Germany-based leader in precision oncology and the field of Targeted Radionuclide Therapy, closed a convertible loan financing totaling €90m (USD 109m). The round was led by Petrichor Healthcare Capital Management with participation of additional undisclosed investors. Under the terms of the agreement, the loan will convert into shares of ITM in the event of certain future financial or other corporate development transactions. In conjunction with the financing, Tadd Wessel, Founder and Managing Partner at Petrichor, will join ITM’s supervisory board. Further details of the financing were not disclosed.

Steffen schusterTadd wesselTargeted radionuclide therapyPetrichor healthcare capital managementManaging partnerChief executive officerPrecision oncologyஸ்டெஃபென் ஸ்கஸ்டர்தாதித் வெசெல்பெட்ரிகோர் சுகாதாரம் மூலதனம் மேலாண்மைநிர்வகித்தல் கூட்டாளர்தலைமை நிர்வாகி அதிகாரிப்ரிஸிஶந் புற்றுநோயியல்

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), (ABCL) - The Daily Biotech Pulse: Osmotica Faces Second FDA Rejection, UK Conditionally Approves AstraZeneca s Vaccine Candidate, Hepion NASH Data

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), (ABCL) - The Daily Biotech Pulse: Osmotica Faces Second FDA Rejection, UK Conditionally Approves AstraZeneca s Vaccine Candidate, Hepion NASH Data
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

South koreaSouth koreanEftilagimod alphaRegeneron pharmaceuticals incDepartment of defenseBiopharma rises on fundEmergent biosolutions incHepion pharmaceuticals incUs patent trademark officeBiopharma incGeisinger health systemTherapeutics incOsmotica pharmaceuticalsModerna incMount sinai health systemOxford university

ClearPoint Neuro, Inc Announces Funding of Additional $7 5M of Existing Convertible Note on Improved Terms

ClearPoint Neuro, Inc. Announces Funding of Additional $7.5M of Existing Convertible Note on Improved Terms Represents Draw of Additional Proceeds from Petrichor Announced in January 2020 IRVINE, Calif., Dec. 29, 2020 (GLOBE NEWSWIRE) ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced an amendment to its January 2020 secured convertible note financing agreement with Petrichor Healthcare Capital Management (“Petrichor”) and PTC Therapeutics, Inc. The amendment, closed today, provides for an additional $7.5 million strategic investment from Petrichor and improves terms relative to the original conversion price and interest rate. The Company intends to use net proceeds to continue funding global product commercialization, external strategic portfolio partnerships, and internal research and development efforts.

United statesHarolda hurwitzJoe burnettTadd wesselJacqueline kellerCompany clearpoint neuro navigation systemClearpoint neuro incFortress investment groupExchange commissionCompany annual report on formTherapeutics incCompany quarterly report on formApplications of the companyCompany smartflowRepresents drawAdditional proceeds